VMAT 2 inhibitor and Antipsychotic use in Individuals with Huntington’s Disease
Objective: To retrospectively investigate whether the concomitant use of VMAT2 inhibitors and antipsychotics in individuals with Huntington's disease (HD) is associated with an increased occurrence…Association between motor symptoms and striatal VMAT2 binding in PD: a PET study
Objective: In this study, we investigate the association between motor symptoms and striatal vesicular monoamine transporter type 2 (VMAT2) binding using 18F-FP-DTBZ PET in PD…Utility of VMAT2 inhibitors in management of stereotypy in children: a series of six patients
Objective: We aim to evaluate the effectiveness of VMAT2 inhibitors in the treatment of stereotypy. Background: Stereotypies are continual, rhythmic, patterned movements that can occur in typically-developing children, and are…Increased vesicular monoamine transporter alleviate MPTP-induced impairment of neurogenesis
Objective: In this study, we employed vesicular monoamine transporter 2–overexpressing mice (VMAT2-HI) to investigate the influence of increased vesicular storage of catacholamines on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced…PPMI driven sample size estimation for clinical trials in Parkinson’s disease
Objective: To utilize clinical, imaging and CSF data from the Parkinson’s Progression Markers Initiative (PPMI) to estimate the sample size for disease modification studies in…Comparing risperidone and olanzapine to tetrabenazine for the management of Huntington’s chorea
Objective: To compare the efficacy of risperidone and olanzapine to tetrabenazine (TBZ) for the management of Huntington’s chorea in Enroll-HD participants. Background: TBZ is provenly-effective…Reduced vesicular storage of catacholamines enhance MPTP-induced death of dopaminergic neurons in locus coeruleus and olfactory bulb
Objective: In this study, we employed heterozygous knockout (vmat2+/-) mice to investigate the influence of reduced vesicular storage of catacholamines on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-impaired dopaminergic neurons…Vmat2 heterozygote mice display motor dysfunction and progressive depressive-like behaviors
Objective: To assess motor and depressive behaviors in mice that are heterozygous for VMAT2 (VMAT2 HT). Background: Dopamine (DA) is compartmentalized by the vesicular monoamine…Low Incidence of Extrapyramidal Symptoms in Subjects with Tardive Dyskinesia Receiving Long-Term Valbenazine (NBI-98854) Treatment
Objective: To assess the emergence of extrapyramidal symptoms (EPS) such as akathisia and parkinsonism in adults with a diagnosis of schizophrenia/schizoaffective disorder or mood disorder…An MCID for AIMS Dyskinesia Total Score Change in Subjects with Tardive Dyskinesia
Objective: To establish a minimal clinically important difference (MCID) for Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score change using data from randomized, double-blind, placebo…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.